New Capital Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$851K Sell
3,254
-9
-0.3% -$2.31K 0.19% 37
2026
Q2
$821K Buy
3,263
+8
+0.2% +$1.72K 0.19% 36
2026
Q1
$708K Buy
3,255
+11
+0.3% +$2.44K 0.17% 38
2025
Q4
$741K Sell
3,244
-10
-0.3% -$2.28K 0.19% 35
2025
Q3
$753K Buy
3,254
+180
+6% +$36.7K 0.2% 33
2025
Q2
$571K Buy
3,074
+74
+2% +$13.8K 0.16% 36
2025
Q1
$629K Hold
3,000
– – 0.18% 29
2024
Q4
$533K Hold
3,000
– – 0.16% 34
2024
Q3
$592K Hold
3,000
– – 0.17% 29
2024
Q2
$515K Hold
3,000
– – 0.16% 36
2024
Q1
$546K Hold
3,000
– – 0.16% 36
2023
Q4
$465K Sell
3,000
-1,500
-33% -$219K 0.15% 38
2023
Q3
$671K Buy
+4,500
New +$661K 0.23% 33
2023
Q1
$717K Hold
4,500
– – 0.27% 31
2022
Q4
$727K Hold
4,500
– – 0.31% 29
2022
Q3
$604K Hold
4,500
– – 0.33% 26
2022
Q2
$684K Sell
4,500
-228
-5% -$34.8K 0.38% 26
2022
Q1
$766K Buy
+4,728
New +$687K 0.55% 25
2018
Q1
– Sell
-151
Closed -$15K – 151
2017
Q4
$15K Hold
151
– – 0.02% 115
2017
Q3
$13K Hold
151
– – 0.02% 123
2017
Q2
$10K Hold
151
– – 0.02% 131
2017
Q1
$10K Hold
151
– – 0.02% 131
2016
Q4
$9K Buy
+151
New +$9.22K 0.01% 127

Other funds holding ABBV

New Capital Management's ABBV Position: Q3 2026 in Review

New Capital Management reduced its AbbVie (ABBV) stake by 0.28% in Q3 2026, selling an estimated $2.31K and leaving 3,254 shares worth $851K. The position accounts for 0.19% of the portfolio, ranked #37.

New Capital Management first reported a position in ABBV in Q4 2016 and has held it in 23 quarters since. 4,280 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • New Capital Management held 3,254 shares of AbbVie worth $851K as of Q3 2026.
  • New Capital Management sold 9 AbbVie shares in Q3 2026, an estimated $2.31K.
  • AbbVie made up 0.19% of New Capital Management's portfolio in Q3 2026, its #37 holding.
  • New Capital Management first reported a position in AbbVie in Q4 2016 and has held it in 23 quarters since.
  • 4,280 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on New Capital Management's 13F filing for Q3 2026, filed 29 Oct 2026.